Indications for Apraclonidine 0.5%:
Short-term adjunctive therapy to reduce elevated IOP.
Remove contact lenses; may reinsert 15min after instillation. 1–2 drops into affected eye(s) 3 times daily. Allow at least 5mins between instillation of other oph drugs.
Clonidine allergy. Concomitant MAOIs.
Monitor visual fields. Severe uncontrolled cardiovascular disease, hypertension, coronary insufficiency. Recent myocardial infarction. Cerebrovascular disease. Raynaud's disease. Thromboangiitis obliterans. History of vasovagal attack. Discontinue if ocular allergic-like reactions occur. Renal or hepatic impairment: closely monitor cardiovascular parameters. Depression. May mask hypoglycemia. Pregnancy. Nursing mothers (1% soln: discontinue nursing temporarily for 1 day of use).
See Contraindications. May potentiate CNS depressants (eg, alcohol, barbiturates, opiates, sedatives, anesthetics). Caution with TCAs, β-blockers, antihypertensives, cardiac glycosides, others (eg, clonidine). Concomitant CV drugs: monitor HR, BP periodically.
Hyperemia, pruritus, dry mouth, itching, discomfort, tearing, dizziness, solmnolence, lid edema, blurred vision, foreign body sensation, dry eye, conjunctivitis, discharge, blanching; tachyphylaxis may develop after 1 month; also in post-laser surgery: upper lid elevation, inflammation, nasal decongestion, mydriasis, irregular HR.
Soln 0.5%—contact supplier; 1% (0.1mL)—2